Legal Challenges Medication Abortion Legislation Medication Abortions Telehealth Public Opinion Public Health Legal Restrictions State Legislation Political Advocacy Public Policy Legislative Actions Chemical Abortions Medication Abortion Statistics Public Health Crisis Abortion Pills Medical Abortions Geographic Disparities Contraceptive Choices Medication Abortion Availability Health Equity State Policies Legal History Legal and Ethical Issues Legal Implications Personal Choices Arizona Abortion Access Act Healthcare Access State Sovereignty State Responses Pro-Life Movement Political Reactions State Regulations Legal Challenges to Abortion Out-of-State Abortion Services Supreme Court Healthcare Policy State Bans State Laws Abortion Laws Telemedicine Crisis Pregnancy Centers Travel Funding Minor Rights Chemical Abortion Health Risks Online Censorship Pro-life Movement Political Implications Drug Regulations Legal Disputes Mifepristone Legal Protections Coerced Abortions Federal Legislation Healthcare Regulations
The court found the Risk Evaluation and Mitigation Strategy changes arbitrary and sent them back to the agency for further review, a ruling that could affect nationwide access to mifepristone.
